VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

Rickettsia rickettsii vaccine using M. vaccae expressing R. rickettsii OmpA Protein
Vaccine Information
  • Vaccine Name: Rickettsia rickettsii vaccine using M. vaccae expressing R. rickettsii OmpA Protein
  • Target Pathogen: Rickettsia spp
  • Target Disease: Spotted Fever, Typhus
  • Vaccine Ontology ID: VO_0011388
  • Type: Recombinant vector vaccine
  • Status: Research
  • ompA gene engineering:
    • Type: Recombinant vector construction
    • Description:
    • Detailed Gene Information: Click Here.
  • Adjuvant: incomplete Freunds adjuvant
  • Immunization Route: Subcutaneous injection
Host Response

Mouse Response

  • Host Strain: C3H/HeN mice
  • Vaccination Protocol: 6–8-week-old male C3H/HeN mice were were inoculated subcutaneously with 1×108 to 5×108 of recombinant M. vaccae transformants containing rompA3006–3960. As a negative control mice were immunized with either PBS or inoculated subcutaneously with M. vaccae/pCR7, another negative control. Booster inoculations were performed 1 month later with the same dose and route. Mice immunized with M. vaccae transformants were given two additional doses of 100 μg per mouse of recombinant rickettsial GST fusion protein OmpA755–1301 suspended in incomplete Freund’s adjuvant with a 1 month interval between the immunizations (Crocquet-Valdes et al., 2001).
  • Challenge Protocol: One month after the last inoculation, all groups of mice were challenged intravenously with three LD50 of R. conorii and observed daily for 2 weeks for morbidity and mortality (Crocquet-Valdes et al., 2001).
  • Efficacy: Immunization with one of the constructs of Mycobacterium vaccae expressing Rickettsia rickettsii OmpA in combination with booster immunization with the homologous recombinant protein protected a significant portion of mice from lethal challenge with the closely related bacterium, R. conorii, in mice (Crocquet-Valdes et al., 2001).
  • Host Ifng (Interferon gamma) response
    • Description: Production of IFN-gamma by antigen-exposed T-lymphocytes of DNA vaccine recipients indicated that cellular immunity had been stimulated. IFN-γ levels in supernatant fluid of rickettsial antigen-stimulated splenocytes from an animal that received both DNA and protein vaccinations were 47% or more higher than the controls that were vaccinated with the vector and GST or were sham-immunized with saline. This observed difference was significant and was seen in spleen cells the day before the challenge (Crocquet-Valdes et al., 2001).
    • Detailed Gene Information: Click Here.
References
Crocquet-Valdes et al., 2001: Crocquet-Valdes PA, Díaz-Montero CM, Feng HM, Li H, Barrett AD, Walker DH. Immunization with a portion of rickettsial outer membrane protein A stimulates protective immunity against spotted fever rickettsiosis. Vaccine. 2001; 20(5-6); 979-988. [PubMed: 11738766].